ImpediMed Limited (ASX: IPD) - Share Price
- Current share price for IPD : $0.005
ImpediMed Limited (IPD), an ASX-listed company, is a medical technology Company that non-invasively measures, monitors and manages fluid status and tissue composition data using bioimpedance spectroscopy (BIS).
IPD General Information +
| ASX Code | IPD |
| Website | N/A |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 18 |
| IPD Share Price | $0.005 |
| Day High | $0.006 |
| Day Low | $0.005 |
| Last Close | $0.005 |
| IPD Share Price Movement | - ( No change ) |
Prices as at 16:40, 25 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
ImpediMed Limited (IPD) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from ImpediMed Limited (IPD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
ImpediMed Limited (IPD) price-sensitive announcements
IPD - Oversubscribed Share Purchase Plan Successfully Completed
ImpediMed Limited announced the successful completion of its oversubscribed Share Purchase
ImpediMed Limited (IPD)
10 Jun 2026 | 9:05 AM
10 Jun 2026 | 9:05 AM
IPD - CEO Business Update
ImpediMed Limited, an Australian medical technology company, provided a business update fr
ImpediMed Limited (IPD)
2 Jun 2026 | 11:42 AM
2 Jun 2026 | 11:42 AM
IPD - Equity Raising Investor Presentation
ImpediMed Limited has announced a transformational equity raising of up to $15.2 million t
ImpediMed Limited (IPD)
4 May 2026 | 10:55 AM
4 May 2026 | 10:55 AM
IPD - ImpediMed announces a successful $15.2 million Capital Raise
ImpediMed Limited, an Australian medical technology company, announced a successful capita
ImpediMed Limited (IPD)
4 May 2026 | 10:55 AM
4 May 2026 | 10:55 AM
ImpediMed Limited (IPD) Recent ASX Announcements
IPD Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$23.24 | -$1.20 | 17.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$19.79 | -$1.00 | -14.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$20.52 | -$1.10 | -3.40% | 0.00 | 0.00 | 0.00% | 0.0% |
IPD Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Cochlear Limited (COH) | $7,420M | 0.0171 | -0.1883 | 0.0862 | 18.9579 | 23.3556 | 21.5030 | 3.79% | 3.06% | 3.26% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $17,901M | 0.1388 | 0.1359 | 0.1882 | 46.0910 | 40.5751 | 34.1474 | 1.42% | 1.52% | 1.72% |
| ImpediMed Limited (IPD) | $22M | 0.1735 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| ResMed Inc. (RMD) | $15,953M | 0.3087 | 9.7634 | 0.0805 | 192.0908 | 17.8466 | 16.5169 | 1.20% | 1.26% | 1.33% |
IPD Directors
| Name | Position | Start Date |
|---|---|---|
| Mr McGregor Grant | Executive Director, Chief Financial Officer | 28 Sep 2023 |
| Mr Andrew John Grant | Non-Executive Director | 28 Sep 2023 |
| Ms Janelle Delaney | Non-Executive Director | 28 Sep 2023 |
| Ms Fiona Bones | Non-Executive Director | 7 Jun 2024 |
| Mr Erik Anderson | Non-Executive Director | 25 Feb 2026 |
| Ms Christine Emmanuel-Donnelly | Non-Executive Director, Non-Executive Chairman | 28 Sep 2023 |
ImpediMed Limited (IPD) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 16 Jun 2026 | DELANEY, Janelle | Issued | Indirect Shares | 10,000,000 | $0.010 | $100,000.000 |
| 16 Jun 2026 | EMMANUEL-DONNELLY, Christine | Issued | Indirect Shares | 10,000,000 | $0.010 | $100,000.000 |
| 16 Jun 2026 | GRANT, Andrew | Issued | Direct Shares | 5,000,000 | $0.010 | $50,000.000 |
See all changes in directors' interest & trades for ImpediMed Limited (IPD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IPD Management
| Name | Position |
|---|---|
| McGregor Grant | Chief Financial & Operating Officer/Executive Director |
| Steven Chen | Chief Medical Officer |
| Scott Savage | Chief Product Officer |
| Katie Newsome | Clinical Program Director |
| Leanne Ralph | Company Secretary |
| Ashley Munoz | Director, Human Resources |
| Julie Kuhlken | Senior Director, Marketing |
| Dennis Schlaht | SVP R&D and Technology |
| Scott Long | SVP Sales, Key Accounts, and Renewals |
| Mike Bassett | VP Business Development and Investor Relations |
IPD Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in ImpediMed Limited (IPD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 174,188,828 (8.58%) | Paradice Investment Management Pty Ltd |
| 115,304,879 (5.68%) | National Nominees Ltd |
IPD Calendar of Events
| Date | Event |
|---|---|
| 02 March 2027 | Report (Interim) |
| 25 February 2027 | Report (Interim) |
| 27 August 2026 | Report (Annual) |
| 27 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
